Stem Cell Transplantation: Non-cancer Disorders

Table of Contents

Table of Contents ............................................ 1
Related Coverage Resources .......................... 1
Overview ...................................................... 2
Coverage Policy ............................................... 2
  Aplastic Anemia and Other Marrow Failure Syndromes .............................................. 2
  Autoimmune Diseases .................................... 2
  Inherited Metabolic Disorders ......................... 3
  Multiple Sclerosis (MS) .................................. 3
  Myelofibrosis .............................................. 4
  Primary Immunodeficiency Disorders .............. 4
  Sickle Cell Disease and Thalassemia Major .... 4
  Polycythemia Vera ........................................ 4
  Type 2 Diabetes Mellitus ............................... 4
General Background ...................................... 4
  Professional Societies/Organizations .............. 5
  Aplastic Anemia and Other Marrow Failure Syndromes .............................................. 8
  Autoimmune Diseases .................................... 8
  Inherited Metabolic Disorders ......................... 10
  Multiple Sclerosis (MS) .................................. 14
  Myelofibrosis .............................................. 15
  Primary Immunodeficiency Disorders .............. 15
  Sickle Cell Disease and Thalassemia Major .... 16
  Polycythemia Vera ........................................ 17
  Type 2 Diabetes Mellitus ............................... 17
Coding/Billing Information .............................. 18
References .................................................. 19

Related Coverage Resources

Autologous Cell Therapy for Cardiac and Peripheral Arterial Disease
Donor Lymphocyte Infusion and Hematopoietic Progenitor Cell (HPC) Boost
Multiple Sclerosis Therapy 1402
Stem Cell Transplantation: Blood Cancers
Stem Cell Transplantation: Solid Tumors
Transplantation Donor Charges
Umbilical Cord Blood Banking

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document (Group Service Agreement, Evidence of Coverage, Summary Plan Description (SPD) or similar plan document) may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for
Overview

This Coverage Policy addresses hematopoietic stem cell transplantation (HSCT) for some non-cancerous disorders.

Coverage Policy

Coverage for hematopoietic stem cell transplantation (HSCT) varies across plans. Refer to the customer's benefit plan document for coverage details.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Hematopoietic Stem Cell Transplantation (HSCT) Coverage Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aplastic Anemia and Other Marrow Failure Syndromes</strong></td>
<td>Allogeneic HSCT is considered medically necessary for the treatment of ANY of the following conditions:</td>
</tr>
<tr>
<td></td>
<td>• severe aplastic anemia</td>
</tr>
<tr>
<td></td>
<td>• Fanconi anemia</td>
</tr>
<tr>
<td></td>
<td>• Diamond-Blackfan anemia</td>
</tr>
<tr>
<td></td>
<td>• Congenital Amegakaryocytic Thrombocytopenia (CAMT)</td>
</tr>
<tr>
<td></td>
<td>• Dyskeratosis Congenita</td>
</tr>
<tr>
<td></td>
<td>• Paroxysmal nocturnal hemoglobinuria (PNH)</td>
</tr>
<tr>
<td></td>
<td>• Shwachman-Diamond Syndrome</td>
</tr>
<tr>
<td><strong>Autoimmune Diseases</strong></td>
<td><strong>Autologous HSCT is considered medically necessary for the treatment of systemic sclerosis (scleroderma) when ALL of the following criteria are met:</strong></td>
</tr>
<tr>
<td></td>
<td>• adult 18 to 69 years of age</td>
</tr>
<tr>
<td></td>
<td>• diffuse cutaneous systemic sclerosis (scleroderma) for 5 years or less with either:</td>
</tr>
<tr>
<td></td>
<td>• Pulmonary involvement with active interstitial lung disease and both:</td>
</tr>
<tr>
<td></td>
<td>• Consistent bronchoalveolar cell composition or ground-glass opacities on computed tomography of the chest</td>
</tr>
<tr>
<td></td>
<td>• Either a forced vital capacity (FVC) or a diffusing capacity of the lung for carbon monoxide (DLco) of less than 70% of the predicted value.</td>
</tr>
<tr>
<td></td>
<td>• Renal involvement</td>
</tr>
<tr>
<td></td>
<td>• Individual does not have ANY of the following:</td>
</tr>
<tr>
<td></td>
<td>• active gastric antral vascular ectasia</td>
</tr>
<tr>
<td></td>
<td>• a DLco of less than 40% of the predicted value</td>
</tr>
<tr>
<td></td>
<td>• an FVC of less than 45% of the predicted value</td>
</tr>
<tr>
<td></td>
<td>• a left ventricular ejection fraction of less than 50%</td>
</tr>
<tr>
<td></td>
<td>• a creatinine clearance of less than 40 ml per minute</td>
</tr>
<tr>
<td></td>
<td>• pulmonary arterial hypertension,</td>
</tr>
<tr>
<td></td>
<td>• more than six months of previous treatment with cyclophosphamide</td>
</tr>
<tr>
<td></td>
<td><strong>HSCT for the treatment of any other autoimmune disease including but not limited to the following is considered experimental, investigational or unproven:</strong></td>
</tr>
<tr>
<td></td>
<td>• autoimmune hemolytic anemia</td>
</tr>
<tr>
<td></td>
<td>• autoimmune hepatitis</td>
</tr>
<tr>
<td></td>
<td>• celiac disease</td>
</tr>
</tbody>
</table>
## Indication

### Hematopoietic Stem Cell Transplantation (HSCT) Coverage Criteria

All allogeneic transplantations must be from an appropriately-matched human leukocyte antigen (HLA) donor.

- Crohn’s disease
- cryptogenic cirrhosis
- dermatomyositis
- immune vasculitis
- juvenile idiopathic arthritis
- neuromyelitis optica
- polymyositis
- rheumatoid arthritis
- systemic lupus erythematosus
- thrombotic thrombocytopenia purpura
- type 1 diabetes mellitus
- ulcerative colitis

### Inherited Metabolic Disorders

Allogeneic HSCT is considered medically necessary for the treatment of ANY of the following inherited metabolic disorders:

- Alpha mannosidosis
- Cerebral X-linked Adrenoleukodystrophy
- Farber disease type 2/3
- Fucosidosis
- Gaucher disease types I and 3
- Hunter syndrome (MPS-II)
- Hurler syndrome (MPS-IH)
- Infantile malignant osteopetrosis
- Krabbe disease (globoid leukodystrophy, GLD)
- metachromatic leukodystrophy (MLD)
- Maroteaux-Lamy syndrome (MPS-VI)
- Sly syndrome (MPS VII)
- Wolman disease
- Niemann-Pick disease type B

**HSCT for the treatment of ANY of the following inherited metabolic disorders is considered experimental, investigational or unproven:**

- Scheie syndrome (MPS-IS)
- Niemann-Pick disease type A
- Sanfilippo disease (MPS-III)

### Multiple Sclerosis (MS)

Autologous HSCT is considered medically necessary for the treatment of multiple sclerosis when ALL of the following criteria are met:

- adult 18 to 55 years of age
- relapsing-remitting* (RR) or secondary progressive* (SP) multiple sclerosis
- Expanded Disability Status Scale (EDSS) score between 2.0 and 6.0
- failed treatment with one or more disease-modifying therapy(ies) (DMT)
- evidence of either (or any) of the following while being treated with DMT:
  - two or more clinical relapses* at separate times but within the previous 12 months
  - one relapse* and a magnetic resonance imaging (MRI) gadolinium-enhancing lesion(s) at a separate time than the relapse but within the previous 12 months

*Definitions:
### Indication

<table>
<thead>
<tr>
<th>Indication</th>
<th>Hematopoietic Stem Cell Transplantation (HSCT) Coverage Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All allogeneic transplantations must be from an appropriately-matched human leukocyte antigen (HLA) donor.</td>
</tr>
<tr>
<td></td>
<td>Relapsing-remitting Multiple Sclerosis (RRMS): A multiple sclerosis course characterized by relapses with stable neurological disability between episodes.</td>
</tr>
<tr>
<td></td>
<td>Secondary Progressive Multiple Sclerosis (SPMS): a progressive course (steadily increasing objectively documented neurological disability independent of relapses) following an initial relapsing-remitting course.</td>
</tr>
<tr>
<td></td>
<td>Relapse: A monophasic clinical episode with patient-reported symptoms and objective findings typical of multiple sclerosis, reflecting a focal or multifocal inflammatory demyelinating event in the CNS, developing acutely or subacutely, with a duration of at least 24 hour, with or without recovery, and in the absence of fever or infection.</td>
</tr>
<tr>
<td>Myelofibrosis</td>
<td>Allogeneic HSCT is considered medically necessary for the treatment of myelofibrosis for symptoms that persist, or worsen despite standard supportive care.</td>
</tr>
<tr>
<td></td>
<td>Autologous HSCT is considered experimental, investigational or unproven for the treatment of myelofibrosis.</td>
</tr>
<tr>
<td>Primary Immunodeficiency Disorders</td>
<td>Allogeneic HSCT is considered medically necessary for the treatment of primary immunodeficiency disorders.</td>
</tr>
<tr>
<td>Sickle Cell Disease and Thalassemia Major</td>
<td>Myeloablative allogeneic HSCT is considered medically necessary for the treatment of a child or young adult at increased risk of complications of sickle cell disease (SCD) or thalassemia major.</td>
</tr>
<tr>
<td></td>
<td>Non-myeloablative allogeneic HSCT for a child or young adult with SCD or thalassemia major is considered experimental, investigational or unproven.</td>
</tr>
<tr>
<td></td>
<td>HSCT for an adult with SCD or thalassemia major is considered experimental, investigational or unproven.</td>
</tr>
<tr>
<td>Polycythemia Vera</td>
<td>HSCT is considered experimental, investigational or unproven for the treatment of polycythemia vera (PV).</td>
</tr>
<tr>
<td>Type 2 Diabetes Mellitus</td>
<td>HSCT for the treatment of type 2 diabetes mellitus is considered experimental, investigational or unproven.</td>
</tr>
</tbody>
</table>

### General Background

Hematopoietic stem cell transplantation (HSCT), also called hematopoietic cell transplantation (HCT) or stem cell transplant, is a type of treatment for cancer (and a few other conditions as well). Bone marrow produces all of the different cells that make up the blood, such as red blood cells, white blood cells, and platelets. All of the cells of the immune system are also made in the bone marrow. All of these cells develop from a type of precursor cell found in the bone marrow, called a "hematopoietic stem cell." Hematopoietic stem cells are found in the peripheral blood and the bone marrow; therefore stem cells can be collected or harvested from either location.

Some of the most effective treatments for cancer, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow. After the treatment, a healthy supply of stem cells is reintroduced, or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. HSCT is a method of replacing immature blood-forming cells in the bone marrow that have been destroyed by drugs, radiation, or disease. It may be autologous (i.e., using a person’s own stem cells) or allogeneic (i.e., using stem cells donated by someone else).
• Autologous transplant — In autologous transplantation, an individual's own hematopoietic stem cells are
removed before the high dose chemotherapy or radiation is given, and they are then frozen for storage
and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned
to the individual, like a transfusion.

• Allogeneic transplant — In allogeneic transplantation, the hematopoietic stem cells come from a donor,
ideally a brother or sister with a similar genetic makeup. If an individual does not have a suitably
matched sibling, an unrelated person with a similar genetic makeup may be used. Under some
circumstances, a parent or child who is only half-matched can also be used; this is termed a
haploidentical transplant. In other circumstances, umbilical cord blood may be used in an umbilical cord
blood transplant.

• Myeloablative transplant — A myeloablative transplantation uses very high doses of chemotherapy or
radiation prior to transplantation with autologous or allogeneic hematopoietic stem cells.

• Non-myeloablative transplant — A non-myeloablative transplantation, sometimes referred to as a "mini"
or reduced intensity transplant, allows an individual to have less intensive chemotherapy before
transplantation with allogeneic hematopoietic stem cells. This approach may be recommended for a
variety of reasons including age, type of disease, other medical issues, or prior therapies.

Contraindications
Many factors affect the outcome of a tissue transplantation; the selection process is designed to obtain the best
result for each individual. The presence of any significant comorbid conditions which would significantly
compromise clinical care and chances of survival is a contraindication to transplant. Relative contraindications
for HSCT include (but are not limited to):

• poor cardiac function (ejection fraction less than 45%)
• poor liver function (bilirubin greater than 2.0 mg/dL and transaminases greater than two times normal),
  unless related to disease
• poor renal function (creatinine clearance less than 50 mL/min)
• poor pulmonary function (diffusion capacity less than 60% of predicted)
• presence of human immunodeficiency virus or active hepatitis B, hepatitis C or human T-cell
  lymphotropic virus type 1 (HTLV-1)
• Karnofsky rating less than 60% and/or Eastern Cooperative Oncology Group (ECOG) performance
  status greater than two

Professional Societies/Organizations
The American Society for Blood and Marrow Transplantation (ASBMT) published a Position Statement on
Autologous Hematopoietic Cell Transplantation for Treatment- Refractory Relapsing Multiple Sclerosis (MS)
(Cohen, et al., 2019). The ASBMT Task Force recommends revising the recommended indication for autologous
hematopoietic stem cell transplantation (aHSCT or AHCT) in MS to "standard of care, clinical evidence
available", for patients with relapsing forms of relapsing-remitting (RR) MS (RRMS or progressive MS with
superimposed activity) who have prognostic factors that indicate a high risk of future disability, including ongoing
clinical relapse or MRI lesion activity despite treatment with available disease-modifying therapy (DMT),
especially if disease activity continues despite treatment with high-efficacy DMTs and/or worsening disability.
This revision of previous "developmental" guideline is based on the evidence from retrospective studies, clinical
trials, and meta-analyses/systematic reviews.

• Patients most likely to benefit from aHSCT include those of relatively younger age with relatively short
disease duration, a relapsing form of MS (RRMS or progressive MS with superimposed activity),
accumulating disability but still ambulatory, and ongoing disease activity despite DMT.

• Patients less likely to benefit: with progressive MS without recent inflammatory disease activity (ie, clinical
relapse or MRI lesion activity within the previous 1 to 2 years) are less likely to benefit.

• Some patients with other demographic or disease characteristics (eg, patients with early MS who have failed
only a limited number of DMTs but are considered at high risk for future disability or some patients with
progressive disease without recent activity) may benefit from aHSCT, but there is less supportive evidence
for aHSCT in those populations (Cohen, et al., 2019).
The European Society for Blood and Marrow Transplantation (EBMT) published Updated Guidelines and Recommendations on Autologous haematopoietic stem cell transplantation and other cellular therapy in Multiple Sclerosis and immune-mediated neurological diseases (Sharrack, et al., 2019). Recommendations include:

- aHSCT should be offered to patients with RRMS with high clinical and MRI inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with Gd-enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months) despite the use of one or more lines of approved DMTs. (Level S/I; Standard of Care, Grade I is Evidence from at least one well executed randomised trial)
- Patients with ‘aggressive’ MS, who develop severe disability in the previous 12 months, are suitable candidates for aHSCT. Given the potential for irreversible disability, such patients may be considered even before failing a full course of DMT (Level CO/II; Clinical option [small patient cohorts show efficacy and acceptable toxicity of the HSCT procedure], Grade II [evidence from at least one well-designed clinical trial without randomisation; cohort or case-controlled analytic studies (preferably from more than one centre); multiple time-series studies; or dramatic results from uncontrolled experiments].
- Patients with secondary progressive MS (SPMS) should be considered for aHSCT, preferably in a prospective clinical trial, only when inflammatory activity is still evident (clinical relapses and Gd-enhancing or new T2 MRI lesions) with documented disability progression in the previous 12 months (Level CO/II).
- Patients with primary progressive MS (PPMS) should be considered for aHSCT, preferably in a prospective clinical trial, only when inflammatory activity is evident (Gd-enhancing and new T2 MRI lesions) with documented evident disability progression in the previous 12 months (Level CO/II).
- Paediatric patients with MS who have breakthrough inflammatory disease with less toxic treatments may be considered for aHSCT (Level CO/II).
- Patients with refractory Chronic inflammatory demyelinating polyneuropathy (CIDP), Myasthenia gravis (MG), Neuromyelitis optica (NMO), Stiff person syndrome (SPS) and systemic autoimmune diseases with neurological manifestations may be considered for aHSCT (Level CO/II) (Sharrack, et al., 2019).

The American Society for Blood and Marrow Transplantation (ASBMT) published a Position Statement on Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation (Sullivan, et al., 2018). Based on high-quality evidence, the ASBMT recommends systemic sclerosis be considered as “standard of care” indication for aHSCT.

The American Society for Blood and Marrow Transplantation (ASBMT) Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation addressed non-malignant diseases (Majhail, et al., 2015).

<table>
<thead>
<tr>
<th>Children (&lt;18 years)</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe aplastic anemia, new diagnosis</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>Severe aplastic anemia, relapse/refractory</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>Fanconi’s anemia</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Dyskeratosis congenita</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Blackfan-Diamond anemia</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>C</td>
<td>N</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>Congenital amegakaryocytic thrombocytopenia</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Severe combined immunodeficiency</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>T cell immunodeficiency, SCID variants</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Wiskott-Aldrich syndrome</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Hemophagocytic disorders</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Lymphoproliferative disorders</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Severe congenital neutropenia</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Chronic granulomatous disease</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Other phagocytic cell disorders</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>IPEX syndrome</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Juvenile rheumatoid arthritis</td>
<td>D</td>
<td>R</td>
</tr>
</tbody>
</table>
### Children (<18 years)

(N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental.)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic sclerosis</td>
<td>D</td>
<td>R</td>
</tr>
<tr>
<td>Other autoimmune and immune dysregulation disorders</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Mucopolysaccharidoses (MPS-I and MPS-VI)</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Other metabolic diseases</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Osteopetrosis</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Globoid cell leukodystrophy (Krabbe)</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Metachromatic leukodystrophy</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Cerebral X-linked Adrenoleukodystrophy</td>
<td>R</td>
<td>N</td>
</tr>
</tbody>
</table>

### Adults

(N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental.)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe aplastic anemia, new diagnosis</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>Severe aplastic anemia, relapse/refractory</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>Fanconi’s anemia</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Dyskeratosis congenita</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>C</td>
<td>N</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>D</td>
<td>N</td>
</tr>
<tr>
<td>Hemophagocytic syndromes, refractory</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Mast cell diseases</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Common variable immunodeficiency</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Wiskott-Aldrich syndrome</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Chronic granulomatous disease</td>
<td>R</td>
<td>N</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>Polymyositis-dermatomyositis</td>
<td>N</td>
<td>D</td>
</tr>
</tbody>
</table>

The National Marrow Donor Program (NMDP) lists the following Clinician Disease Specific Transplant Indications and Outcomes (2019) related to non-cancer:

- **Severe Aplastic Anemia and Other Marrow Failure Syndromes**
  - acquired or congenital aplastic anemia
  - Fanconi anemia
  - Diamond-Blackfan anemia
- **Inherited Metabolic Disorders. Allogeneic HCT can treat:**
  - Hurler syndrome (MPS I)
  - Hunter syndrome (MPS II)
  - Maroteaux-Lamy syndrome (MPS VI)
  - Sly syndrome (MPS VII)
  - Cerebral X-linked adrenoleukodystrophy
  - Globoid-cell leukodystrophy (Krabbe disease)
  - Metachromatic leukodystrophy
  - Gaucher disease
  - Fucosidosis
  - Alpha-mannosidosis
  - Aspartylglycosaminuria
  - Mucolipidosis II (I-cell disease)
Medical Coverage Policy: 0535

- Wolman syndrome
- Immune Deficiency Diseases. Primary immunodeficiencies comprise more than 130 different disorders. Allogeneic hematopoietic cell transplantation (HCT) is the only potential cure for the severe forms of the immune deficiency diseases:
  - severe combined immunodeficiency (SCID),
  - Wiskott-Aldrich syndrome,
  - Omenn syndrome,
  - X-linked lymphoproliferative syndrome,
  - chronic granulomatous disease,
  - leukocyte adhesion deficiency,
  - DiGeorge syndrome
  - and others.
- Sickle cell disease
- Thalassemia
- Other Non-Malignant Diseases
  - Myeloproliferative neoplasms (MPN) (including BCR-ABL-negative myeloproliferative neoplasms, Polycythemia vera, Essential thrombocytosis)
  - Myelofibrosis
  - Hemophagocytic lymphohistiocytosis (HLH)

(National Marrow Donor Program, 2019).

Literature Review

Aplastic Anemia and Other Marrow Failure Syndromes: Aplastic anemia and other anemias is a bone marrow failure syndrome. Bone marrow failure syndromes are a class of rare diseases with abnormal or absent hematopoiesis in one or more cell lines, and include acquired or congenital aplastic anemia, and other anemias. Most patients are diagnosed in childhood, mainly by presenting with hematologic findings such as single-cell or pancytopenia, myelodysplastic syndromes, or leukemia, particularly acute myeloid leukemia.

Acquired aplastic anemia is thought to have an autoimmune component in many patients, and immunosuppressive therapy is therefore a typical front-line therapy. Patients with aplastic anemia are classified based on the severity of their marrow aplasia. Allogeneic HSCT is considered a standard of care option for an individual with severe aplastic anemia (SAA). SAA requires at least two of the following:

- neutrophil count is less than 500 cells per microliter
- reticulocyte count is less than 20,000 per microliter
- platelet count is less than 20,000 per microliter

Inherited bone marrow failure syndromes are a heterogeneous group of rare hematological disorders characterized by the impairment of hematopoiesis, which harbor specific clinical presentations and pathogenic mechanisms. Some of these syndromes may progress through clonal evolution, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Most prominent are failures of DNA repair such as Fanconi Anemia and much rarer failure of ribosomal apparatus, e.g., Diamond Blackfan Anemia or of telomere elongation such as Dyskeratosis Congenita (DC). In these congenital disorders, HSCT is often a consideration. However, HSCT will not correct the underlying disease and possible co-existing extra-medullary (multi)-organ defects, but will improve bone marrow failure (Fioredda, et al., 2018; Kojima, et al., 2018; Dalle, et al., 2016).

Inherited bone marrow failure syndromes are a heterogeneous group of rare hematological disorders characterized by the impairment of hematopoiesis, which harbor specific clinical presentations and pathogenic mechanisms. Some of these syndromes may progress through clonal evolution, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Most prominent are failures of DNA repair such as Fanconi Anemia and much rarer failure of ribosomal apparatus, e.g., Diamond Blackfan Anemia or of telomere elongation such as Dyskeratosis Congenita (DC). In these congenital disorders, HSCT is often a consideration. However, HSCT will not correct the underlying disease and possible co-existing extra-medullary (multi)-organ defects, but will improve bone marrow failure (Fioredda, et al., 2018; Kojima, et al., 2018; Dalle, et al., 2016).

Paroxysmal nocturnal hemoglobinuria (PNH) and Shwachman-Diamond Syndrome (SDS) are not addressed by the ASBMT (Majhail, et al., 2015). Brodsky et al. (2014) states that allogeneic BMT following non-myeloablative conditioning regimens can cure PNH. Nelson et al. (2018) notes that hematopoietic stem cell transplant remains the only curative therapy for SDS individuals with severe aplastic anemia or malignant transformation.

Autoimmune Diseases: Autoimmune diseases are a very heterogeneous group of disorders with varying etiologies, levels of organ involvement and prognosis. Standard treatment for autoimmune diseases generally consists of immunosuppression, anti-inflammatory and/or anti-malarial medication, and supportive care. Dose escalation of immunosuppressive medication utilizing HSCT has been proposed for individuals who are
refractory to standard treatment or have disease considered to be life-, or organ-threatening. Crohn's disease, juvenile idiopathic arthritis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and type 1 diabetes mellitus are some of the more common types of autoimmune diseases.

Systemic sclerosis: Evidence from three randomized trials (ASSIST [Burt, et al., 2011]; ASTIS [van Laar, et al., 2014]; SCOT [Sullivan, et al., 2018]) demonstrate that autologous HSCT is more effective than conventional immunosuppressive therapies at inducing a better long-term survival, ameliorating skin thickening and stabilizing internal organ function in severe SSC. The patients who can likely benefit from autologous HSCT are those with a rapid progressive and diffuse skin involvement, persistent high levels of disease activity, and mild initial organ damage. A limited window of opportunity exists for HSCT treatment in SSC as severe irreversible organ involvement precludes transplantation. Autologous HSCT should be considered for carefully selected patients with early rapidly progressive diffuse SSc refractory to conventional therapy, and a poor prognosis for survival. Risks of HSCT include, but are not limited to, early treatment-related mortality, gonadal failure and secondary autoimmune diseases. Center experience and specialist expertise are further important factors for improving outcomes of autologous HSCT strategies (Walker, et al., 2018; Shouval, et al., 2018).

The European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc) (Kowal-Bielecka, et al., 2017) state HSCT should be considered for treatment of selected patients with rapidly progressive SSc at risk of organ failure. In view of the high risk of treatment-related side effects and of early treatment-related mortality, careful selection of patients with SSc for this kind of treatment and the experience of the medical team are of key importance (Strength of Recommendation A).

Hayes, Inc. published a Health Technology Assessment on Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Systemic Sclerosis on July 19, 2019.


Hayes concludes that “An overall moderate-quality body of evidence regarding the use of autologous HSCT for treatment of rapidly progressive, poor-prognosis SSc suggests that HSCT consistently improves skin involvement and QOL, with rates of overall survival ranging from 72% to 89.5% (3-6 years of follow-up). When compared with DMARDs, HSCT was associated with better overall survival, less disease-related mortality, longer survival without relapse or progression, less skin involvement, and higher scores on some measures of QOL and function. While reported rates of AEs and treatment-related mortality were high in some studies, the available evidence suggests that patients with rapidly progressive, poor-prognosis SSc could benefit from treatment with HSCT. Continued research is needed to identify the safest transplant procedures for specific patients.”

Crohn disease: A systematic review and meta-analysis was completed evaluating the efficacy and safety of autologous HSCT for refractory Crohn's disease (Qui, et al., 2017). The authors concluded that autologous HSCT could be a complicated treatment with relatively high mortality and significantly high efficacy for refractory CD, which should be used with caution. However, more RCTs of larger samples using refined and standardized protocols and longer period of follow-up time are needed to further assess the outcomes of autologous HSCT therapy. A randomized clinical trial determined that for Crohns patients (with impaired quality of life from refractory Crohn disease not amenable to surgery despite treatment with 3 or more immunosuppressive or biologic agents and corticosteroids), HSCT, compared with conventional therapy, did not result in a statistically significant improvement in sustained disease remission at one year and was associated with significant toxicity (Hawkey, et al., 2015). Additional randomized controlled clinical trials are needed. At this time the role of HSCT has not been determined for this indication.

Diabetes Mellitus (DM): A meta-analysis on the safety and efficiency of different types of stem cell therapy for both type 1 and type 2 DM was completed (El-Badawy et el., 2016). The authors concluded the most promising therapeutic outcome was shown in mobilized marrow CD34+ stem cells; however, well-designed large scale randomized studies considering the stem cell type, cell number, and infusion method in DM patients are needed. Although results are promising, there is insufficient evidence to establish the role of autologous or allogeneic HSCT for the treatment of type I diabetes mellitus. Professional society support in the form of published consensus guidelines is also lacking.
Juvenile Idiopathic Arthritis (JIA): There is limited data to determine the safety and effectiveness of hematopoietic stem-cell transplantation (HSCT) for the treatment of juvenile idiopathic arthritis (JIA) (Silva, et al., 2018; Brinkman, et al., 2007). The role of HSCT for this indication has not yet been established.

Rheumatoid Arthritis (RA): Data are limited in the published peer-reviewed scientific literature. Park et al. (2018) conducted a phase IA feasibility trial with human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs). No short-term safety concerns were identified for the RA patients with moderate disease activity despite treatment with methotrexate. Small trials with uncontrolled study design limit the ability to determine safety and effectiveness of autologous or allogeneic HSCT for this indication. The role of HSCT in the treatment of RA has not yet been established.

Systemic Lupus Erythematosus (SLE): Lupus is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. Leone et al. (2017) conducted a systematic review of available evidence on HSCT therapy in patients with SLE and antiphospholipid syndrome (APS). The authors concluded that preliminary results of HSCT as a therapeutic option for SLE appear promising. However, the rate of adverse effects confines this option to very selected cases of SLE patients resistant or refractory to standard approaches. Further studies are warranted in order to assess the safety of the procedure for both the occurrence of secondary autoimmune disease and the rate of infection.

Inherited Metabolic Disorders: Inherited metabolic disorders, also called inborn errors of metabolism or congenital metabolic disorders, are caused by genetic mutation, creating an enzyme deficiency that leads to an inability to breakdown metabolic waste products. The result is a progressive cellular accumulation of toxic substances, which damages organs, tissues, and the central nervous system. If left untreated, these disorders result in a progressive disease with neurological and psychomotor retardation, skeletal abnormalities, and life-threatening cardiac and pulmonary complications. Allogeneic HCT can arrest this progressive deterioration by introducing enzyme-producing cells that can cross the blood-brain barrier. There are several types of disorders, including:

- lysosomal storage diseases
- glycogen storage diseases
- disorders of carbohydrate metabolism
- disorders of amino acid metabolism
- organic acidemias
- disorders of fatty acid metabolism
- mitochondrial disorders

On behalf of the Agency for Healthcare Research and Quality (AHRQ), Ratko et al. (2012) conducted a systematic review of the literature to evaluate the benefits and harms of HSCT versus standard therapies or disease natural history in children with malignant solid tumors, inherited metabolic diseases, and autoimmune diseases. The authors noted that the evidence was insufficient for most pediatric indications. The overall grade of evidence strength was classified within the following four categories: high - further research is very unlikely to change confidence in the estimate of effect; moderate - further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate of effect; low - further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate; and insufficient - any estimate of effect is very uncertain. Regarding the effect of HSCT compared to standard therapy, symptom management, or natural disease progression for metabolic disorders in children, AHRQ noted the following:

- Evidence suggesting a benefit of HSCT for overall survival:
  - Wolman’s disease compared to disease natural history (high strength)
- Evidence suggested a benefit of HSCT for neuromuscular symptoms:
  - Farber’s disease Type 2/3 compared to symptom management and disease natural history (high strength)
- Evidence suggesting a benefit of HSCT for neurocognitive symptoms:
  - Infantile ceroid lipofuscinosis compared to symptom management or disease natural history (low strength)
Attenuated form of MPS (mucopolysaccharidosis) II (Hunter’s disease) compared to enzyme-replacement therapy (ERT) (low strength)

- Evidence suggesting a benefit of HSCT for neurodevelopmental symptoms:
  - Attenuated and severe forms of MPS II (Hunter’s disease) compared to ERT (low strength)

- Evidence suggesting no benefit of single HSCT for overall survival:
  - Niemann-Pick Type A compared to symptom management (low strength)

- Evidence suggesting no benefit of HSCT for neurodevelopmental symptoms:
  - Gaucher Type III compared to ERT (low strength)
  - Juvenile form of GM1, juvenile Tay-Sachs compared to symptom management or disease natural history (both low strength)
  - MPS III (Sanfilippo) compared to symptom management, substrate reduction therapy, or disease natural history (low strength)

- Evidence suggesting no benefit of HSCT for neurocognitive symptoms:
  - Severe form of MPS II (Hunter’s disease) compared to symptom management or disease natural history (low strength)
  - MPS III (Sanfilippo) compared to symptom management, substrate reduction therapy, or disease natural history (low strength)
  - Gaucher Type III compared to ERT (moderate strength)

- Insufficient evidence to draw conclusions on the benefit or harm on overall survival with single allogeneic HSCT compared with symptom management and/or disease natural history for the following indications:
  - Rapidly Progressive Diseases
    - mucolipidosis II (I-cell disease)
    - Gaucher disease type II
    - cystinosis
    - infantile free sialic acid disease
  - Slowly Progressive Diseases
    - Niemann-Pick type C
    - MPS IV (Morquio syndrome)
    - aspartylglucosaminuria
    - Fabry’s disease
    - β-mannosidosis
    - mucolipidosis III
    - mucolipidosis IV
    - glycogen storage disease type II (Pompe disease)
    - Salla disease
    - adrenomyeloneuropathy
  - Diseases With Both Rapidly and Slowly Progressive Forms
    - galactosialidosis (type unspecified)
    - Sandhoff disease (type unspecified)
    - Farber’s disease type I
    - infantile GM1 gangliosidosis
    - juvenile GM1 gangliosidosis
    - infantile Tay-Sachs
    - juvenile Tay-Sachs
    - juvenile ceroid lipofuscinosis

Additional clinical studies investigating specific Inherited metabolic disorders include but are not limited to, the following:

Aspartylglucosaminuria is a very rare deficiency of the lysosomal enzyme. Aspartylglucosaminidase causes the accumulation of a substance known as aspartylglucosamine in the body, resulting in disorders in the various body systems. The majority of cases are reported in Finland. Treatment of aspartylglucosaminuria is generally symptomatic and supportive.
Farber’s Disease includes acid ceramidase deficiency and Farber’s lipogranulomatosis. Type 1 is the more severe form which has central nervous system involvement. Patients with the milder form, Type 2/3 with either no or mild central nervous system symptoms, can live to their teenage years with chronic respiratory failure as the most common cause of death. Farber’s disease is characterized by three classic symptoms: a hoarse voice or weak cry, small lumps of fat under the skin and in other tissues (lipogranulomas), and swollen and painful joints. Treatment for Farber’s disease is symptomatic and supportive. Corticosteroid drugs may provide some relief for joint pain. According to the National Institute of Neurological Disorders and Stroke (NINDS, 9/17/2018), bone marrow transplants may improve granulomas (small masses of inflamed tissue) on individuals with little or no lung or nervous system complications.

Fucosidosis may also be referred to as alpha-L-fucosidase deficiency. The treatment of fucosidosis is directed toward the specific symptoms that are apparent in each individual. Research in bone marrow transplant for fucosidosis and related lysosomal diseases is ongoing. Several case reports in the literature note that HSCT could reduce the severity and retard the progression of clinical neurological deterioration.

Gaucher disease is rare, but is the most common type of lysosomal storage disorder. It is characterized by a deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain lipids, specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. Researchers have identified three distinct forms of Gaucher disease separated by the absence (type 1) or presence and extent (type 2 or type 3) of neurological complications.

- Gaucher disease type 1 is also known as non-neuronopathic, because it does not involve the central nervous system (brain and spinal cord).
- Gaucher disease type 2, also known as acute neuronopathic Gaucher disease, occurs in newborns and infants and is characterized by neurological complications due to the abnormal accumulation of glucocerebroside in the brain.
- Gaucher disease type 3, also known as chronic neuronopathic Gaucher disease, occurs during the first decade of life. In addition to blood and bone abnormalities, affected individuals develop neurological complications that develop and progress slower than in Gaucher disease type 2.

Treatment is individualized for each patient depending on the type of Gaucher disease. Type 1 Gaucher disease is considered treatable and mild, because it does not involve neurological symptoms since the brain is not affected. Type 2 is not considered to be treatable at this point due to the quick and irreversible brain damage in the infantile years. Type 3 still involves neurological damage, but these symptoms progress more slowly than in type 2. Enzyme replacement therapy (ERT) has proven effective for individuals with Gaucher disease type 1. ERT has not been effective in reducing or reversing certain neurological symptoms associated with Gaucher disease types 2 and 3. Other treatment is generally symptomatic and supportive.

Mucolipidoses (ML) are a group of inherited metabolic diseases in which abnormal amounts of carbohydrates and fatty materials (lipids) accumulate in cells. Damage to the cells occurs, causing symptoms that range from mild learning disabilities to severe intellectual impairment and skeletal deformities. No cures or specific therapies for ML currently exist. Therapies are generally geared toward treating symptoms and providing supportive care to the child.

- Mucolipidosis I (Sialidosis) is characterized by a deficiency of the enzyme alpha-neuraminidase. There are two sub-types, type I and type II.
- Mucolipidosis II (I-cell disease or Inclusion-cell disease or ML II) is characterized by deficiencies of the enzymes neuraminidase and beta-galactosidase. The standard treatment of I-cell disease is symptomatic and supportive. Antibiotics are often prescribed for respiratory infections and yearly flu shots are important. Physical therapy is encouraged to maintain joint function and mobility as long as possible. Experimental therapies are aimed at treating I-cell disease as early as possible. Bone marrow replacement transplantation has been attempted for the treatment of this disorder but the benefit was limited.
- Mucolipidosis III (Pseudo-Hurler polydystrophy) is characterized by the accumulation of certain complex carbohydrates (mucopolysaccharides) and fatty substances (mucolipids) in various tissues of the body. The symptoms of this disorder are less severe than those of I-cell disease.
- Mucolipidosis IV (ML IV) is caused by harmful alterations of a protein in the cell that is believed to be involved in the movement of molecules such as calcium across cell membranes.
Mucopolysaccharidoses (MPS disorders) are caused by the deficiency of one of ten specific lysosomal enzymes, resulting in an inability to metabolize complex carbohydrates (mucopolysaccharides) into simpler molecules. The accumulation of these large mucopolysaccharides in the cells of the body causes a number of physical symptoms and abnormalities. Bone marrow transplantation as a way to replace defective enzymes has been studied as a treatment for individuals with mucopolysaccharidosis. The effectiveness of BMT has varied greatly. Physical characteristics may improve, such as cloudy corneas may become clear, the size of an abnormally enlarged liver and spleen may decrease, and mucopolysaccharide levels may drop. Skeletal malformations are unaffected. The effect on neurological symptoms varies considerably. Because BMT is a procedure that carries significant risks, it should only be considered in selected cases.

- **MPS I** (Hurler Disease, MPS Disorder I) has three subtypes of varying severity:
  - Scheie Syndrome (MPS IS) – milder form of MPS I
  - Hurler-Scheie Syndrome (MPS IH/S) – an intermediate form of MPS I
  - Hurler Syndrome (MPS IH) – the most severe form of MPS I

Laronidase ( Aldurazyme), an enzyme replacement therapy, is the first treatment FDA-approved specifically for Hurler syndrome. Other treatment is symptomatic and supportive.

- **MPS II** (Hunter syndrome) is caused by lack of the enzyme iduronate sulfatase. Previously, MPS II was classified as severe and attenuated based on severity. More recently, the terms slowly progressive and early progressive have been suggested. MPS II is now considered a continuous spectrum of disease. An enzyme replacement therapy, idursulfase (Elaprase), was approved as a treatment for MPS II. Other treatments of MPS II are symptomatic and supportive.

- **MPS III** (Sanfilippo disease or syndrome) includes four subtypes of MPS III: types A, B, C and D.

  - Type A is caused by a defect in the GALNS gene. People with type A do not have an enzyme called N-acetylgalactosamine-6-sulfatase.
  - Type B is caused by a defect in the GLB1 gene. People with type B do not produce enough of an enzyme called beta-galactosidase.

The body needs these enzymes to break down long strands of sugar molecules called keratan sulfate. In both types, abnormally large amounts of glycosaminoglycans build up in the body.

- **MPS IV** (Morquio syndrome) includes two forms:
  - Type A is caused by a defect in the GALNS gene. People with type A do not have an enzyme called N-acetylgalactosamine-6-sulfatase.
  - Type B is caused by a defect in the GLB1 gene. People with type B do not produce enough of an enzyme called beta-galactosidase.

- **MPS VI** (Maroteaux-Lamy syndrome) occurs in three types: a classic severe type, an intermediate type, and a mild type. The syndrome is characterized by a deficiency in the enzyme arylsulfatase B (also called N-acetylgalactosamine-4-sulfatase), which leads to an excess of dermatan sulfate in the urine.

- **MPS VII** (Sly syndrome) is characterized by a deficiency of the lysosomal enzyme known as beta-glucuronidase.

- **MPS IX** is also known as hyaluronidase deficiency.

Niemann-Pick disease causes harmful quantities of lipids accumulate in the brain, spleen, liver, lungs, and bone marrow. There is currently no cure for Niemann-Pick disease. Treatment is supportive. Restricting one's diet does not prevent the buildup of lipids in cells and tissues. The disorder may be best thought of as a spectrum of disease.

- At the severe end of the spectrum is a fatal neurodegenerative disorder that presents in infancy (Niemann-Pick disease type A).
- At the mild end of the spectrum, affected individuals have no or only minimal neurological symptoms and survival into adulthood is common (Niemann-Pick disease type B). Type B, also called juvenile onset, usually occurs in the pre-teen years with symptoms that include ataxia and peripheral neuropathy. Treatment is aimed at addressing the symptoms present in each individual. Bone marrow transplantation has been attempted in a few individuals. Researchers are working to develop additional options for treatment, including enzyme replacement and gene therapy.
- **Type C** may appear early in life or develop in the teen or adult years. There are two types, NPC1 and NPC2. Affected individuals may have extensive brain damage that can cause an inability to look up and down, difficulty in walking and swallowing, and progressive loss of vision and hearing. NPC1 is also called subacute juvenile form or chronic neuronopathic form.
Multiple Sclerosis (MS) A recently published trial is the Multiple Sclerosis International Stem Cell Transplant (MIST) randomized clinical trial (Burt, et al., 2019). This trial compared the effect of nonmyeloablative HSCT versus disease-modifying therapy (DMT) on disease progression in patients with relapsing-remitting multiple sclerosis (RRMS).

- Inclusion criteria were relapsing-remitting MS according to McDonald criteria, age 18 to 55 years, 2 or more clinical relapses or 1 relapse and MRI gadolinium-enhancing lesion(s) at a separate time within the previous 12 months despite receiving treatment with disease-modifying therapy (DMT; such as interferons, glatiramer acetate, fingolimod, natalizumab, or dimethyl fumarate), and an Expanded Disability Status Scale (EDSS) score between 2.0 and 6.0.
- Exclusion criteria were primary or secondary progressive multiple sclerosis; hereditary neurologic diseases; pregnancy; pulmonary, cardiac, renal, or liver dysfunction; abnormal platelet or white blood cell counts; active infection; prior treatment with alemtuzumab or mitoxantrone; or use of natalizumab within the prior 6 months, fingolimod within 3 months, or, for teriflunomide (which undergoes extensive enterohepatic recycling), failure of oral cholestyramine to decrease teriflunomide to a plasma concentration of less than 0.02 μg/mL.
- Patients randomized to the DMT group received an FDA-approved DMT of higher efficacy or a different class than the therapy they were taking at the time of randomization, based on the judgment of their treating neurologist. In addition to DMT, patients in this group could receive immune-modulating or immunosuppressive drugs such as methylprednisolone, rituximab, intravenous immunoglobulin, or cyclophosphamide. After at least 1 year of treatment, patients in the DMT group who experienced progression of disability could cross over to receive HSCT.
- Patients randomized to the HSCT group, use of DMT was discontinued and variable washout periods were observed before admission for HSCT (6 months for natalizumab, 3 months for fingolimod and dimethyl fumarate, and 4 months for rituximab). Patients who were receiving teriflunomide underwent either oral cholestyramine or activated charcoal clearance. Interferons and glatiramer acetate were continued until mobilization. After HSCT, patients did not receive immune-based therapies unless they experienced clinical relapse, new lesions on MRI, or both.

Among 110 randomized patients, 103 remained in the trial, with 98 evaluated at one year and 23 evaluated yearly for five years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in three patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months in the DMT group (p< .001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (p< .001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events) (Burt, et al., 2019).

The Autologous Haematopoietic Stem Cell Transplantation trial in MS (ASTIMS) is a multicenter, randomized, phase II study designed to assess the effect of aHSCT versus mitoxantrone (MTX) on the disease activity in MS, measured by MRI in the 4 years following treatment (Mancardi, et al., 2015).

- Inclusion criteria included clinically defined MS, a secondary progressive (SP) or relapsing-remitting (RR) form that accumulates disability between relapses, with a documented worsening during the last year (1 step of EDSS, or 0.5 when EDSS is between 5.5 and 6.5), in spite of conventional therapy (interferon-b or glatiramer acetate or immunosuppressive therapy), and presence of one or more gadolinium (Gd)-enhancing areas on MRI. The EDSS score had to be between 3.5 and 6.5.
- A total of 21 patients were recruited from 7 centers in 2 countries, Italy and Spain. All the patients had a follow-up of 4 years, and only 2 cases were followed for 3 years. Nine patients were randomized in the aHSCT and 12 in the MTX arm. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosinearabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by aHSCT or MTX 20 mg every month for 6 months.

AHSCT significantly reduced the annualized relapse rate (ARR) as compared to MTX: ARR was 0.6 for the MTX arm and 0.19 for the aHSCT treatment group and the difference was statistically significant, despite the low power of the study for this endpoint (p = 0.026). Progression occurred at the end of follow-up in 48% of cases in the MTX arm and in 57% of the aHSCT-treated group. There was no statistical difference between the 2 groups.
No difference in EDSS change at year 1, 2, 3, and 4 was found between the treatment arms. This study is limited by small population size (Mancardi, et al., 2015).

Two meta-analysis have recently been performed:

- Ge et al. (2019) evaluated 732 transplant patients from 18 trials and found:
  - The PFS was 75%, and the estimate of disease activity-free survival was 61% with 48-month follow-up. Subgroups analysis showed that low- and intermediate-intensity regimens were associated with higher PFS 80%.
  - Relapsing remitting MS (RRMS) benefited more from aHSCT than other MS subtypes with PFS 85%. Patients with Gd+ lesions at baseline MRI responded better to aHSCT with PFS 77%.
  - The estimate of TRM was 1.34%, and the overall mortality was 3.58%. TRM was significantly higher in high-intensity regimen studies (3.13%) and in older studies (1.93%) performed before 2006.

- Sormani et al. (2017) evaluated 764 transplant patients from 15 trials and found:
  - The pooled estimate of transplant-related mortality (TRM) was 2.1%. TRM was higher in older studies (p=0.014) and in studies with a lower proportion of patients with RRMS (p=0.028).
  - A higher baseline EDSS (p=0.013) was also significantly associated with a higher TRM.
  - Pooled rate of progression was 17.1% at 2 years and 23.3% at 5 years. Lower 2-year progression rate was significantly associated with higher proportions of patients with RRMS (p=0.004).
  - The pooled proportion of no evidence of disease activity (NEDA) patients at 2 years was 83% and at 5 years was 67%.


**Myelofibrosis:** Myelofibrosis is considered a myeloproliferative neoplasm. Three other disorders are commonly classified as MPNs: chronic myeloid leukemia, essential thrombocythemia and polycythemia vera. Also called primary myelofibrosis (PMF) or idiopathic myelofibrosis, it is characterized by replacement of the bone marrow by fibrous scar tissue, which reduces the ability of the marrow to produce red blood cells. Myelofibrosis may occur as a secondary characteristic of polycythemia vera or essential thrombocytemia. Most therapeutic interventions are directed toward symptom palliation and supportive measures. Current medical therapeutic options for patients with primary myelofibrosis, myelofibrosis after polycythemia, or essential thrombocytopenia have not demonstrated an impact on disease course. Some individuals with primary myelofibrosis have been treated with allogeneic or autologous stem cell transplantation. Because stem cell transplants can cause severe, even life-threatening complications, they are usually employed as a therapy for patients who have failed standard treatment and who have relapsed or have refractory disease.

The National Comprehensive Cancer Network (NCCN®) Clinical Practice Guideline on Myeloproliferative Neoplasms, NCCN (v.3.2019, September 4, 2019) states that HCT is the only potential curative treatment option resulting in long-term remissions for patients with MF. However, the use of myeloablative conditioning is associated with higher rates of non-relapse mortality (MS-14). NCCN also addresses polycythemia vera and thrombocytopenia and does not discuss HSCT under treatment options (MS-25).

**Primary Immunodeficiency Disorders:** When part of the immune system is either absent or not functioning properly, it can result in an immune deficiency disease. When the cause of this deficiency is hereditary or genetic, it is called a primary immunodeficiency disease (PIDD). Researchers have identified more than 300 different kinds of PIDD. Primary immunodeficiency disorders, also known as congenital or inherited immunodeficiency disorders, are inherited disorders of immune system function, predisposing affected individuals to an increased rate and severity of infection and malignancy. Allogeneic hematopoietic cell transplantation (HCT) is the only potential cure for the severe forms of some of the immune deficiency diseases.

Primary immunodeficiency disorders are often classified according to the affected components of the immune system or immunologic phenotype. Although hundreds of primary immunodeficiency syndromes have been identified, less than 20 disorders account for over 90% of the known cases. Some of the more commonly occurring disorders include the following:
- B-cell (antibody) deficiencies
  - X-linked agammaglobulinemia
  - combined variable immunodeficiency (CVID)
  - hyper-IgM syndrome
  - selective IgA deficiency
- Combined T-cell and B-cell (antibody) deficiencies
  - severe combined immunodeficiency (SCID, bubble boy syndrome, Omenn syndrome, variant SCID)
  - partial combined immunodeficiency (CID)
  - Wiskott-Aldrich syndrome (WAS)
- T-Cell deficiencies
  - DiGeorge syndrome
- Defective phagocytes
  - Chediak-Higashi syndrome
  - chronic granulomatous disease
  - leukocyte adhesion defect
- Complement deficiencies
  - hereditary angioedema
- Deficiencies/cause unknown
  - hyper-IgE syndrome
  - chronic mucocutaneous candidiasis
- Defects in innate immunity
  - anhidrotic ectodermal hyperplasia (NEMO deficiency)
  - X-linked IgM syndrome
  - X-linked lymphoproliferative syndrome (XLP, Duncan Disease, Epstein-Barr Virus Susceptibility)
- Autoinflammatory disorders
  - tumor necrosis factor (TNF) receptor periodic fever
  - hyper-IgD syndrome

The American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology 'Practice parameter for the diagnosis and management of primary immunodeficiency' (Bonilla, et al., 2015) lists hematopoietic stem cell therapy as a possible therapeutic option for several immunodeficiency disorder categories and diagnoses. Here are some examples:

- Combined immunodeficiencies (CIDs)
- Immunodeficiency syndromes (Wiskott-Aldrich syndrome)
- Immune dysregulation (familial hemophagocytic lymphohistiocytosis [FHL]; autoimmune lymphoproliferative syndrome [ALPS]; immunodeficiency, polyendocrinopathy, X-linked [IPEX])
- Phagocytic cell defects (neutropenia, chronic granulomatous disease [CGD]; leukocyte adhesion deficiency [LAD]; mendelian susceptibility to mycobacterial disease [MSMD])
- Innate immune defects: (nuclear factor kB essential modulator [NEMO] deficiency, other NF-kB defects; warts, hypogammaglobulinemia, immunodeficiency, myelokathexis [WHIM] syndrome).

**Sickle Cell Disease and Thalassemia Major**: SCD is a group of disorders that affects hemoglobin. People with this disorder have sickle or crescent-shaped red blood cells. SCD encompasses many sickling syndromes caused by abnormal sickle hemoglobin. The most common are sickle cell anemia (Hb SS), sickle-hemoglobin C disease (Hb SC), sickle-beta plus thalassemia, and sickle-beta zero thalassemia. The disease follows a variable clinical course which may include complications such as severe anemia, painful sickle cell crises, organ damage due to iron overload, acute chest syndrome, refractory pain, stroke, and premature death. Although supportive care, drug therapies, and red blood cell transfusions can ease symptoms and extend lifespan, allogeneic hematopoietic cell transplantation (HCT) is the only potential cure for SCD. Generally, clinical trials have included children and young adults up to 24 years in age. Individuals with SCD can decrease the chance of complications by staying as stay healthy as possible (e.g., up to date vaccinations). An individual is at increased risk of further complications based on their personal history of recurrent severe SCD complications.
A consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party provided consensus-based recommendations on indications for HSCT. Regarding children and adolescents with thalassemia major, the panel recommends young patients with an available HLA identical sibling should be offered HSCT as soon as possible before development of iron overload and iron-related tissue damage. Regarding adults, the panel recommends HSCT should be offered within controlled trials to adults who have been well-chelated since infancy. Regarding HSCT for SCD, the panel notes young patients with symptomatic SCD who have an HLA-matched sibling donor should be transplanted as early as possible, preferably at preschool age (Angelucci, et al., 2014).

Thalassemia major is a hereditary anemia resulting from defects in hemoglobin production. There are two types of thalassemia, alpha and beta, depending on which of the two hemoglobin chains is involved. Alpha and beta thalassemia have both mild (i.e., minor) and severe (i.e., major) forms. The severe form of this disease is known as beta thalassemia major, Cooley’s anemia, thalassemia major or Mediterranean anemia. Although advances in supportive care and drug therapies have significantly improved the prognosis in beta thalassemia major, hematopoietic cell transplantation (HCT) remains the only treatment with a potential to cure this hemoglobinopathy.

**Polycythemia Vera:** Polycythemia vera (PV) is considered a myeloproliferative neoplasm. PV, also called polycythemia rubra vera, is a rare, acquired, chronic myeloproliferative neoplasm resulting from a mutation to a single hematopoietic stem cell in the marrow. Less common synonyms include splenomegalic polycythemia, Osler disease, polycythemia with chronic cyanosis, and myelopathic polycythemia. PV is characterized by an abnormal increase in the number of red and white blood cells as well as platelets, with red blood cell overproduction being predominant. The natural history of the disorder is characterized by a lifelong propensity for thrombotic complications and late-onset disease transformation into both myelofibrosis and acute myeloid leukemia.

There is insufficient evidence in the published peer-reviewed scientific literature regarding the safety and effectiveness of HSCT for PV. HSCT has been proposed as a potential treatment for PV; however, transplantation during the polycythemic phase of the disease is rarely appropriate. For those patients in whom myeloid metaplasia with myelofibrosis develops or the disease evolves to acute myelogenous leukemia (AML), HSCT may be investigated as a possible treatment option at that time.


**Type 2 Diabetes Mellitus:** Type 2 DM is the most common form of diabetes. With this disorder the pancreas makes insulin but doesn’t use it efficiently and blood glucose levels rise higher than normal. Proponents are studying if HSCT can reduce exogenous insulin requirement while maintaining target HbA1c and an improvement in stimulated C-peptide response in patients with Type 2 DM. Several studies have been published. Study limitations include short-term follow-up only and small study population. In a Systematic Review, Hwang et al. (2019) suggests HSCT may be effective in improving the β cell function in T2DM; “however, the observed effect should be interpreted with caution due to the significant heterogeneity and high risk of bias within the studies. Further verification through a rigorously designed study is warranted.” There is insufficient evidence to demonstrate improved outcomes with HSCT for the treatment of type 2 DM. Further, there is a lack of professional society support in the form of published consensus guidelines. The role of HSCT has not been established for this indication.

**American Board of Internal Medicine’s (ABIM) Foundation Choosing Wisely® Initiative**

The American Society for Blood and Marrow Transplantation and the Canadian Blood and Marrow Transplant Group states ‘Don’t routinely use peripheral blood stem cells for patients with aplastic anemia when a suitable bone marrow donor is available due to a higher risk of graft-versus-host disease’ (January 2018).

**Centers for Medicare & Medicaid Services (CMS)**
- National Coverage Determinations (NCDs): STEM CELL Transplantation (Formerly 110.8.1) (110.23), last revised 1/27/2016. Coverage Policy is broader in scope than NCD. Refer to the CMS NCD table of contents link in the reference section.
- Local Coverage Determinations (LCDs): No LCDs found.

Use Outside of the US
Applicable information included above.

**Coding/Billing Information**

**Note:**
1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
<tr>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td>38208</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td>38209</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor</td>
</tr>
<tr>
<td>38210</td>
<td>Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Transplant preparation of hematopoietic progenitor cells; tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Transplant preparation of hematopoietic progenitor cells; red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Transplant preparation of hematopoietic progenitor cells; platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic lymphocyte infusions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem-cell transplantation, allogeneic</td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition</td>
</tr>
</tbody>
</table>

Considered Experimental/Investigational/Unproven when used to report any non-covered indication as noted in the policy statements above:
<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
<tr>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td>38208</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td>38209</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor</td>
</tr>
<tr>
<td>38210</td>
<td>Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Transplant preparation of hematopoietic progenitor cells; tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Transplant preparation of hematopoietic progenitor cells; red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Transplant preparation of hematopoietic progenitor cells; platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic lymphocyte infusions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem-cell transplantation, allogeneic</td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition</td>
</tr>
</tbody>
</table>


References


73. Racke MK, Imitola J. Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2017 Apr 1;74(4):392-394


